Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin after PCI in coronary artery disease with type 2 diabetes
ChiCTR2100047856Phase 4Recruiting
- Sponsor
- Yuebei People's Hospital
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dapagliflozin in coronary arteriosclerosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Yuebei People's Hospital. Primary endpoints: maximal oxygen uptake and endothelium-dependent vasodilatation function. Started Jul 2021; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
coronary arteriosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100047856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047856.